Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 30

1.

Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib.

Mulligan G, Mitsiades C, Bryant B, Zhan F, Chng WJ, Roels S, Koenig E, Fergus A, Huang Y, Richardson P, Trepicchio WL, Broyl A, Sonneveld P, Shaughnessy JD Jr, Bergsagel PL, Schenkein D, Esseltine DL, Boral A, Anderson KC.

Blood. 2007 Apr 15;109(8):3177-88. Epub 2006 Dec 21.

2.

Proteasome inhibition: novel therapy for multiple myeloma.

Kaufman JL, Lonial S.

Onkologie. 2006 Apr;29(4):162-8. Epub 2006 Mar 29. Review.

PMID:
16601373
3.

Position statement on the use of bortezomib in multiple myeloma.

Morgan GJ, Davies FE, Cavenagh JD, Jackson GH; United Kingdom Myeloma Forum (UKMF); Haematology Oncology Task Force of the British Committee for Standards in Haematology.

Int J Lab Hematol. 2008 Feb;30(1):1-10. doi: 10.1111/j.1751-553X.2007.01020.x. Review.

PMID:
18190461
4.

Proteasome inhibition in multiple myeloma.

Kropff M, Bisping G, Wenning D, Berdel WE, Kienast J.

Eur J Cancer. 2006 Jul;42(11):1623-39. Epub 2006 Jul 3. Review.

PMID:
16820291
5.

[Clinical development of a proteasome inhibitor, bortezomib, for the treatment of myeloma and lymphoma].

Tobinai K.

Rinsho Ketsueki. 2007 Jun;48(6):451-7. Review. Japanese. No abstract available.

PMID:
17633092
6.

Bortezomib in combination with other therapies for the treatment of multiple myeloma.

Orlowski RZ.

J Natl Compr Canc Netw. 2004 Nov;2 Suppl 4:S16-20. Review.

PMID:
19791424
7.

Proteasome inhibition for treatment of multiple myeloma: clinical update.

Stadtmauer EA.

J Natl Compr Canc Netw. 2004 Nov;2 Suppl 4:S10-5. Review.

PMID:
19795531
8.

Bortezomib for multiple myeloma.

Popat R, Joel S, Oakervee H, Cavenagh J.

Expert Opin Pharmacother. 2006 Jul;7(10):1337-46. Review.

PMID:
16805719
9.

Bortezomib as an antitumor agent.

Roccaro AM, Hideshima T, Richardson PG, Russo D, Ribatti D, Vacca A, Dammacco F, Anderson KC.

Curr Pharm Biotechnol. 2006 Dec;7(6):441-8. Review.

PMID:
17168660
10.
11.

Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature.

Badros A, Goloubeva O, Dalal JS, Can I, Thompson J, Rapoport AP, Heyman M, Akpek G, Fenton RG.

Cancer. 2007 Sep 1;110(5):1042-9. Review.

12.

Response to bortezomib and activation of osteoblasts in multiple myeloma.

Zangari M, Yaccoby S, Cavallo F, Esseltine D, Tricot G.

Clin Lymphoma Myeloma. 2006 Sep;7(2):109-14. Review.

PMID:
17026821
13.

Bortezomib in the front-line treatment of multiple myeloma.

Richardson PG, Mitsiades C, Schlossman R, Ghobrial I, Hideshima T, Munshi N, Anderson KC.

Expert Rev Anticancer Ther. 2008 Jul;8(7):1053-72. doi: 10.1586/14737140.8.7.1053. Review.

PMID:
18588451
14.

New drugs for myeloma.

Richardson PG, Mitsiades C, Schlossman R, Munshi N, Anderson K.

Oncologist. 2007 Jun;12(6):664-89. Review.

15.

Bortezomib in multiple myeloma.

Mateos MV, San Miguel JF.

Best Pract Res Clin Haematol. 2007 Dec;20(4):701-15. Review.

PMID:
18070714
16.

The emerging role of novel therapies for the treatment of relapsed myeloma.

Richardson PG, Hideshima T, Mitsiades C, Anderson KC.

J Natl Compr Canc Netw. 2007 Feb;5(2):149-62. Review.

PMID:
17335684
17.

Bortezomib in multiple myeloma.

Terpos E, Roussou M, Dimopoulos MA.

Expert Opin Drug Metab Toxicol. 2008 May;4(5):639-54. doi: 10.1517/17425255.4.5.639 . Review.

PMID:
18484921
18.

Targeting the proteasome as a therapeutic strategy against haematological malignancies.

Orlowski RZ, Zeger EL.

Expert Opin Investig Drugs. 2006 Feb;15(2):117-30. Review.

PMID:
16433592
19.

The potential of proteasome inhibitors in cancer therapy.

Sterz J, von Metzler I, Hahne JC, Lamottke B, Rademacher J, Heider U, Terpos E, Sezer O.

Expert Opin Investig Drugs. 2008 Jun;17(6):879-95. doi: 10.1517/13543784.17.6.879 . Review.

PMID:
18491989
20.

An update on drug combinations for treatment of myeloma.

Srikanth M, Davies FE, Morgan GJ.

Expert Opin Investig Drugs. 2008 Jan;17(1):1-12. Review.

PMID:
18095914

Supplemental Content

Support Center